Long COVID is defined as a chronic condition that develops following a SARS-CoV-2 infection, persisting for at least three months. It presents as a complex and multifaceted syndrome, most common symptoms include fatigue, breathlessness, and neurological impairments, with researchers identifying patterns of respiratory and multi-system complaints. According to a CDC survey, an estimated 6.4% of U.S. adults have experienced Long COVID, with prevalence varying geographically. Factors such as age, sex, genetics, acute disease severity, pre-existing conditions, and socioeconomic status are potential predictors of long COVID. Vaccination has shown promise in reducing the likelihood of developing Long COVID. The impact of long COVID extends beyond individuals, affecting health systems, economies, and societies. Currently, no standardized diagnostic or treatment guidelines exist for Long COVID. Management strategies focus on symptom relief, with non-pharmacological interventions and conservative therapies for respiratory and neurological symptoms. Emerging diagnostic tools and treatments, such as micro clot detection, biomarker assays, and antiviral drugs like Paxlovid, show potential in improving patient outcomes. Despite the official end of the pandemic, millions continue to suffer from Long COVID, highlighting the need for ongoing research and tailored management approaches to address this persistent public health challenge.